120 related articles for article (PubMed ID: 23242177)
1. ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression.
Jang JY; Jeon YK; Lee CE; Kim CW
Int J Oncol; 2013 Feb; 42(2):574-82. PubMed ID: 23242177
[TBL] [Abstract][Full Text] [Related]
2. ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma.
Jang JY; Lee YS; Jeon YK; Lee K; Jang JJ; Kim CW
Exp Mol Med; 2013 Jan; 45(1):e3. PubMed ID: 23306701
[TBL] [Abstract][Full Text] [Related]
3. ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
Baik SH; Lee J; Lee YS; Jang JY; Kim CW
Exp Mol Med; 2016 Mar; 48(3):e222. PubMed ID: 27012708
[TBL] [Abstract][Full Text] [Related]
4. Combined RNA interference of adenine nucleotide translocase-2 and ganciclovir therapy in hepatocellular carcinoma.
Kim JE; Hwang MH; Lee HW; Lee SW; Lee J; Ahn BC
Nucl Med Biol; 2013 Nov; 40(8):987-93. PubMed ID: 24054501
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma.
Liu L; Li W; Wei X; Cui Q; Lou W; Wang G; Hu X; Qian C
Gene Ther; 2013 Jan; 20(1):84-92. PubMed ID: 22318090
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
[TBL] [Abstract][Full Text] [Related]
7. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
Jang JY; Jeon YK; Choi Y; Kim CW
Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
[TBL] [Abstract][Full Text] [Related]
8. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y; Yeganeh M; Donates YC; Tobelaim WS; Chababi W; Mayhue M; Yoshimura A; Ramanathan S; Saucier C; Ilangumaran S
Oncogene; 2015 Nov; 34(46):5718-28. PubMed ID: 25728680
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
Lu AQ; Lv B; Qiu F; Wang XY; Cao XH
Oncol Rep; 2017 Apr; 37(4):2071-2078. PubMed ID: 28350139
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma.
Chu PY; Yeh CM; Hsu NC; Chang YS; Chang JG; Yeh KT
Swiss Med Wkly; 2010; 140():w13065. PubMed ID: 20648401
[TBL] [Abstract][Full Text] [Related]
11. Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.
Jang JY; Jeon YK; Kim CW
BMC Cancer; 2010 Jul; 10():391. PubMed ID: 20650008
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats.
Bagnyukova TV; Tryndyak VP; Muskhelishvili L; Ross SA; Beland FA; Pogribny IP
Cell Cycle; 2008 Oct; 7(20):3202-10. PubMed ID: 18843197
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis.
Chen Q; Yin D; Zhang Y; Yu L; Li XD; Zhou ZJ; Zhou SL; Gao DM; Hu J; Jin C; Wang Z; Shi YH; Cao Y; Fan J; Dai Z; Zhou J
Cell Death Dis; 2017 Jun; 8(6):e2906. PubMed ID: 28661477
[TBL] [Abstract][Full Text] [Related]
14. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.
Niwa Y; Kanda H; Shikauchi Y; Saiura A; Matsubara K; Kitagawa T; Yamamoto J; Kubo T; Yoshikawa H
Oncogene; 2005 Sep; 24(42):6406-17. PubMed ID: 16007195
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.
Khan MGM; Ghosh A; Variya B; Santharam MA; Ihsan AU; Ramanathan S; Ilangumaran S
BMC Cancer; 2020 Aug; 20(1):774. PubMed ID: 32807134
[TBL] [Abstract][Full Text] [Related]
17. Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver.
Yeganeh M; Gui Y; Kandhi R; Bobbala D; Tobelaim WS; Saucier C; Yoshimura A; Ferbeyre G; Ramanathan S; Ilangumaran S
Oncogene; 2016 Aug; 35(32):4200-11. PubMed ID: 26725321
[TBL] [Abstract][Full Text] [Related]
18. Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: a meta-analysis.
Liu M; Cui LH; Li CC; Zhang L
Eur J Cancer Prev; 2015 Nov; 24(6):470-83. PubMed ID: 25853848
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis.
Long XR; He Y; Huang C; Li J
Int J Oncol; 2014 Jun; 44(6):1915-22. PubMed ID: 24714841
[TBL] [Abstract][Full Text] [Related]
20. Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1.
Huang C; Li H; Wu W; Jiang T; Qiu Z
Oncol Rep; 2013 Sep; 30(3):1223-30. PubMed ID: 23817566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
